secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0000950170-23-002534
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus licenses Nectin-4 ADC CRB-701 from CSPC, announces 1-for-30 reverse stock split
--------------------------------------------------------------------------------

- Exclusive license for CRB-701 (Nectin-4 ADC) from CSPC; upfront $7.5M, up to $685M in milestones/royalties.
- CRB-701 is clinical-stage with FDA IND clearance; Phase 1 in China; US trial planned 2024.
- Reverse stock split 1:30 effective Feb 14, 2023 to regain Nasdaq $1.00 bid price compliance.
- Corbus maintains cash runway through Q2 2024, per CEO Yuval Cohen.
- Territory includes US, Canada, EU, UK, Australia; CSPC retains rest of world.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023002534/0000950170-23-002534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023002534/crbp-20230209.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer